Biotest
Stefanie Fas has a diverse work experience in the pharmaceutical industry. Stefanie currently serves as the Head of Quality Control at Biotest AG and has been in this role since October 2021. Prior to this, they held the position of Director Quality Control Analytics at Biotest AG from November 2018 to September 2021. Before joining Biotest AG, they worked at AbbVie as a Technical Lead for New Biological Entities from November 2016 to October 2018. Stefanie also has experience as a Group Leader in Analytical Development and Validation at Merck Sharp & Dohme from August 2012 to March 2016. Stefanie Fas worked as a Scientist at Crucell from May 2011 to June 2012. Earlier in their career, they held research positions at Kenta Biotech AG from December 2005 to September 2011 and at Gansser Consulting as a Scientific Assistant from October 1999 to May 2000.
Stefanie Fas obtained their Intermediate exam in Biochemistry from Ruhr University Bochum in 1998. Stefanie then pursued a Diploma in Biochemistry from Witten/Herdecke University, which they completed in the year 2001. In the same year, they also conducted their Diploma thesis at Stanford University. Stefanie went on to further their education at Witten/Herdecke University and the German Cancer Research Center (DKFZ), where they earned a PhD in Immunology, Cell Biology, and Biochemistry in 2005.
This person is not in the org chart
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.